((自动化翻译由路透提供，请见免责声明 ))
11月11日 - ** 疗法开发商Neurogene 股价盘后下跌46.9%至37.99美元
** 该公司称，预计 (link)，不会继续推进其巴顿氏病基因疗法的开发。
** 称这是在FDA拒绝了该公司向FDA提交的再生医学先进疗法(RMAT) 基因疗法申请后做出的决定
** 如果一种疗法用于治疗严重或危及生命的疾病或病症，且初步临床证据显示该疗法有可能满足未满足的医疗需求，则该疗法有资格获得RMAT称号。
** 公司表示，目前正在评估开发项目的选择方案
** 巴顿氏病是一种影响神经系统的罕见遗传性致命疾病
** 截至上日收盘，股价年累计涨幅超过一倍
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.